Heidelberg Pharma AG (WL6):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Heidelberg Pharma AG (WL6) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C9765
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:63
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:ドイツ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Heidelberg Pharma AG (Heidelberg Pharma) formerly, Wilex AG is a biopharmaceutical company. The company develops therapeutic and diagnostic product candidates for the treatment and specific detection of various cancers. Heidelberg Pharma’s pipeline products are focused on treating multiple myeloma, prostate cancer, hematological cancers, metastatic pancreatic cancers, leukemia, non- metastatic ccRCC, kidney cancers and solid tumors. Through its subsidiaries it also provides preclinical contract research services and an antibody drug conjugate (ADC) technology platform. Heidelberg Pharma is headquartered in Ladenburg, Germany.

Heidelberg Pharma AG (WL6) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Heidelberg Pharma AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Heidelberg Pharma AG, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Heidelberg Pharma AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Heidelberg Pharma AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Heidelberg Pharma AG, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Heidelberg Pharma AG, Pharmaceuticals & Healthcare, Deal Details 12
Partnerships 12
Telix Pharma Enters into Licensing Agreement with Wilex 12
Magenta Therapeutics Enters into Multi-Target Research Agreement with Heidelberg Pharma 13
Heidelberg Pharma Enters into Research Agreement with Takeda Pharma 14
Nordic Nanovector Enters into Research Agreement with Heidelberg Pharma 15
Heidelberg Pharma Enters into Agreement with Celonic 16
Advanced Proteome Therapeutics Enters into Agreement with Heidelberg Pharma 17
MabVax Therapeutics Enters into Co-Development Agreement with Heidelberg Pharma 18
Licensing Agreements 19
Magenta Therapeutics Enters into Licensing Agreement with Heidelberg Pharma 19
Heidelberg Pharma Enters into Licensing Agreement with University of Texas MD Anderson Cancer Center 20
Heidelberg Pharma Exercises Option for Licensing Agreement with Max Delbruck Center 21
RedHill Biopharma Enters into Licensing Agreement with Wilex for Mesupron 22
Wilex Enters Into Licensing Agreement With Link Health For Mesupron 23
Equity Offering 24
Heidelberg Pharma Raises USD22.8 Million in Rights Offering of Shares 24
Wilex Raises USD5.4 Million in Rights Offering of Shares 25
Wilex to Raise USD4.7 Million in Rights Offering of Shares 26
Wilex Raises USD1.81 Million in Private Placement of Shares 27
Wilex Raises USD0.86 Million in Rights Offering of Shares 28
Wilex Raises USD4.4 Million in Right Issue of Shares 29
Wilex Completes Private Placement Of Shares For US$12.4 Million 30
Wilex Completes Rights Offering Of Shares For US$7.8 Million 31
Wilex Completes Rights Offering Of Shares For US$12.6 Million 32
Debt Offering 33
Heidelberg Pharma Raises USD17.5 Million in Private Placement of Bonds 33
Asset Transactions 34
UCB Pharma Re-Acquires Rights For Antibody Program From Wilex For Non-Oncology Indications 34
Heidelberg Pharma AG – Key Competitors 35
Heidelberg Pharma AG – Key Employees 36
Heidelberg Pharma AG – Locations And Subsidiaries 37
Head Office 37
Other Locations & Subsidiaries 37
Recent Developments 38
Financial Announcements 38
Oct 11, 2018: Heidelberg Pharma AG: Interim management statement on the first nine months of 2018 38
Jul 12, 2018: Heidelberg Pharma reports on first half -year 40
Apr 12, 2018: Heidelberg Pharma: Interim Management Statement on the First Three Months of 2018 42
Mar 22, 2018: Heidelberg Pharma announces financial figures for fiscal year 2017 and provides business update 44
Oct 09, 2017: WILEX: Interim management statement for the first nine months of 2017 47
Jul 13, 2017: WILEX reports on first half-year 50
Apr 12, 2017: WILEX: Interim management statement on the first three months of 2017 52
Mar 30, 2017: WILEX announces financial figures for the 2016 fiscal year and reports on course of business 54
Product News 56
01/24/2017: Antibody against bone marrow tumor developed at MDC is put into application 56
Product Approvals 57
Oct 20, 2017: RedHill Biopharma Receives FDA Orphan Drug Designation for MESUPRON for Pancreatic Cancer 57
Clinical Trials 58
Nov 13, 2017: Heidelberg Pharma announces results from research collaboration with Heidelberg University and the DKFZ to be presented at ASH Annual Meeting 58
Oct 19, 2017: RedHill Biopharma Announces Poster Presentation at the 2017 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference 59
Sep 20, 2017: WILEX: Subsidiary Heidelberg Pharma to Present the Proprietary ATAC Technology Platform at the Annual World ADC Summit 60
Sep 18, 2017: RedHill Biopharma Receives Notice of Allowance for a New U.S. Patent Covering use of MESUPRON in Combination Therapy for cancers 61
Other Significant Developments 62
Oct 19, 2018: WILEX successfully completes change of name to Heidelberg Pharma 62
Appendix 63
Methodology 63
About GlobalData 63
Contact Us 63
Disclaimer 63

List of Tables
Heidelberg Pharma AG, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Heidelberg Pharma AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Heidelberg Pharma AG, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Heidelberg Pharma AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Heidelberg Pharma AG, Deals By Therapy Area, 2012 to YTD 2018 9
Heidelberg Pharma AG, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Telix Pharma Enters into Licensing Agreement with Wilex 12
Magenta Therapeutics Enters into Multi-Target Research Agreement with Heidelberg Pharma 13
Heidelberg Pharma Enters into Research Agreement with Takeda Pharma 14
Nordic Nanovector Enters into Research Agreement with Heidelberg Pharma 15
Heidelberg Pharma Enters into Agreement with Celonic 16
Advanced Proteome Therapeutics Enters into Agreement with Heidelberg Pharma 17
MabVax Therapeutics Enters into Co-Development Agreement with Heidelberg Pharma 18
Magenta Therapeutics Enters into Licensing Agreement with Heidelberg Pharma 19
Heidelberg Pharma Enters into Licensing Agreement with University of Texas MD Anderson Cancer Center 20
Heidelberg Pharma Exercises Option for Licensing Agreement with Max Delbruck Center 21
RedHill Biopharma Enters into Licensing Agreement with Wilex for Mesupron 22
Wilex Enters Into Licensing Agreement With Link Health For Mesupron 23
Heidelberg Pharma Raises USD22.8 Million in Rights Offering of Shares 24
Wilex Raises USD5.4 Million in Rights Offering of Shares 25
Wilex to Raise USD4.7 Million in Rights Offering of Shares 26
Wilex Raises USD1.81 Million in Private Placement of Shares 27
Wilex Raises USD0.86 Million in Rights Offering of Shares 28
Wilex Raises USD4.4 Million in Right Issue of Shares 29
Wilex Completes Private Placement Of Shares For US$12.4 Million 30
Wilex Completes Rights Offering Of Shares For US$7.8 Million 31
Wilex Completes Rights Offering Of Shares For US$12.6 Million 32
Heidelberg Pharma Raises USD17.5 Million in Private Placement of Bonds 33
UCB Pharma Re-Acquires Rights For Antibody Program From Wilex For Non-Oncology Indications 34
Heidelberg Pharma AG, Key Competitors 35
Heidelberg Pharma AG, Key Employees 36
Heidelberg Pharma AG, Subsidiaries 37

List of Figures
Heidelberg Pharma AG, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Heidelberg Pharma AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Heidelberg Pharma AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Heidelberg Pharma AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Heidelberg Pharma AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Heidelberg Pharma AG, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Heidelberg Pharma AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Heidelberg Pharma AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

★海外企業調査レポート[Heidelberg Pharma AG (WL6):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Kelda Group Ltd:企業の戦略・SWOT・財務情報
    Kelda Group Ltd - Strategy, SWOT and Corporate Finance Report Summary Kelda Group Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • The Williams Companies, Inc.:企業の戦略・SWOT・財務分析
    The Williams Companies, Inc. - Strategy, SWOT and Corporate Finance Report Summary The Williams Companies, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • Entreprise Tunisienne d’Activites Petrolieres:企業の戦略的SWOT分析
    Entreprise Tunisienne d'Activites Petrolieres - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors …
  • Albireo Pharma Inc (ALBO):医療機器:M&Aディール及び事業提携情報
    Summary Albireo Pharma Inc (Albireo), formerly Biodel Inc., focuses on the development and commercialization of innovative bile acid modulators to treat orphan pediatric liver diseases and other liver and gastrointestinal (GI) disorders and diseases where inappropriate flow of bile causes severe med …
  • Targa Resources Corp.:企業の戦略・SWOT・財務情報
    Targa Resources Corp. - Strategy, SWOT and Corporate Finance Report Summary Targa Resources Corp. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Natus Medical Incorporated (BABY):医療機器:M&Aディール及び事業提携情報
    Summary Natus Medical Incorporated (Natus) is a provider of newborn and neurology healthcare products. It offers wide range of products for the screening, diagnosis, detection, treatment, monitoring and tracking of ailments in newborn. Natus offers products for diagnostic hearing assessment in child …
  • Murphy Oil Corporation:企業の戦略・SWOT・財務情報
    Murphy Oil Corporation - Strategy, SWOT and Corporate Finance Report Summary Murphy Oil Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Fresenius Kabi AG:企業の戦略的SWOT分析
    Fresenius Kabi AG - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and serv …
  • Berkley Renewables Inc (BKS)-石油・ガス分野:企業M&A・提携分析
    Summary Berkley Renewables Inc (Berkley) is a venture firm that focuses on capturing opportunities in renewable energy, life sciences, and oil & gas sectors. The company essentially carries out power generation through the management and operation of solar photovoltaic plants . It also undertakes th …
  • PT Ramayana Lestari Sentosa Tbk:戦略・SWOT・企業財務分析
    PT Ramayana Lestari Sentosa Tbk - Strategy, SWOT and Corporate Finance Report Summary PT Ramayana Lestari Sentosa Tbk - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …
  • Brooks MacDonald Group PLC (BRK):企業の財務・戦略的SWOT分析
    Brooks MacDonald Group PLC (BRK) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and wea …
  • Vetoquinol SA (VETO):企業の財務・戦略的SWOT分析
    Summary Vetoquinol SA (Vetoquinol) is a veterinary pharmaceutical company that develops, produces and distributes veterinary drugs and non-medicinal products. The company provides pain management, anti-infective, hygiene and care, pest control, behavior, internal medicine, reproduction, behaviour an …
  • Mission Therapeutics Ltd:製薬・医療:M&Aディール及び事業提携情報
    Summary Mission Therapeutics Ltd (Mission) is a provider of deubiquitylating enzyme drug discovery and development programs. The company develops USP30, USP10 and UHCL1 for patients with mitochondria diseases, neurodegeneration, inflammation and others. the company uses its proprietaryDUB platform t …
  • MicuRx Pharmaceuticals Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary MicuRx Pharmaceuticals Inc (MicuRx) is a developer of antibiotics for drug-resistant bacterial infections. The company develops a pipeline of antimicrobial agents using its proprietary drug discovery platform to treat both gram-positive and gram-negative bacterial infections. It offers produ …
  • Shanghai Fosun Pharmaceutical (Group) Co Ltd (600196)-製薬・医療分野:企業M&A・提携分析
    Summary Shanghai Fosun Pharmaceutical (Group) Co Ltd (Fosun Pharma), a subsidiary of Shanghai Fosun High Technology (Group) Co Ltd is a drug company that offers pharmaceutical products, medical diagnostic products and medical device products. The company’s pharmaceutical products include metabolism …
  • R-Biopharm AG:医療機器:M&Aディール及び事業提携情報
    Summary R-Biopharm AG (R-Biopharm), a subsidiary of Rohm Gmbh & Co KG, is a developer of test solutions for clinical diagnostics and food and feed analysis. The company offers test systems in the areas of infectological stool diagnostics, serological infection and allergy diagnostics for clinical di …
  • Bolu Cimento Sanayii AS:企業の戦略・SWOT・財務情報
    Bolu Cimento Sanayii AS - Strategy, SWOT and Corporate Finance Report Summary Bolu Cimento Sanayii AS - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Currence Holding B.V.
    Currence Holding B.V. - Strategy, SWOT and Corporate Finance Report Summary Currence Holding B.V. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Bangladesh Power Development Board:電力:M&Aディール及び事業提携情報
    Summary Bangladesh Power Development Board (BPDB) is an integrated electric utility. It generates using gas, furnace, diesel, hydro, coal and solar; and imports power from India. The company operates independent power plants /SIPP, rental power plant and REB using steam turbine, gas turbine, combine …
  • Vision International People Group Public Limited:戦略・SWOT・企業財務分析
    Vision International People Group Public Limited - Strategy, SWOT and Corporate Finance Report Summary Vision International People Group Public Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆